
Market Cap
$136.10B
P/E Ratio
18.23
52W High
$28.75
52W Low
$23.11
Analyst Ratings
No analyst coverage available for PFE.
AI Fair Value Estimate
Get an AI analyst's take on whether PFE looks cheap or expensive — a fair-value range with plain-English reasoning, in one click.
Upgrade to PROInsider Trading50 recent filings
Buys
40
Sells
10
Reported value
$34.60M
| Date | Insider | Type | Shares | Price | Value | Owned |
|---|---|---|---|---|---|---|
| Jun 15, 2026 | BOURLA, ALBERT Director, Chairman & CEO | Buy | 23 | $26.00 | $598.00 | - |
| Jun 9, 2026 | DAMICO, JENNIFER B. SVP & Controller | Sell | 2,000 | $25.70 | $51,400.00 | - |
| May 29, 2026 | BOURLA, ALBERT Director, Chairman & CEO | Buy | 23 | $26.18 | $602.14 | - |
| May 15, 2026 | BOURLA, ALBERT Director, Chairman & CEO | Buy | 24 | $25.33 | $607.92 | - |
| Apr 30, 2026 | BOURLA, ALBERT Director, Chairman & CEO | Buy | 22 | $26.70 | $587.40 | - |
| Apr 23, 2026 | BLAYLOCK, RONALD E Director | Buy | 7,687 | $26.67 | $205,000.00 | - |
| Apr 23, 2026 | GOTTLIEB, SCOTT Director | Buy | 7,687 | $26.67 | $205,000.00 | - |
| Apr 23, 2026 | NORA, JOHNSON SUZANNE M Director | Buy | 7,687 | $26.67 | $205,000.00 | - |
| Apr 23, 2026 | LITTMAN, DAN R. Director | Buy | 7,687 | $26.67 | $205,000.00 | - |
| Apr 23, 2026 | TARAPOREVALA, CYRUS Director | Buy | 7,687 | $26.67 | $205,000.00 | - |
| Apr 23, 2026 | ECHEVARRIA, JOSEPH Director | Buy | 7,687 | $26.67 | $205,000.00 | - |
| Apr 23, 2026 | NARAYEN, SHANTANU Director | Buy | 7,687 | $26.67 | $205,000.00 | - |
| Apr 23, 2026 | QUINCEY, JAMES Director | Buy | 7,687 | $26.67 | $205,000.00 | - |
| Apr 23, 2026 | BUCKLEY, MORTIMER J Director | Buy | 7,687 | $26.67 | $205,000.00 | - |
| Apr 23, 2026 | DESMOND-HELLMANN, SUSAN Director | Buy | 7,687 | $26.67 | $205,000.00 | - |
| Apr 23, 2026 | SMITH, JAMES C Director | Buy | 7,687 | $26.67 | $205,000.00 | - |
| Apr 15, 2026 | BOURLA, ALBERT Director, Chairman & CEO | Buy | 22 | $27.19 | $598.18 | - |
| Apr 14, 2026 | BOURLA, ALBERT Director, Chairman & CEO | Buy | 911 | $27.11 | $24,697.21 | - |
| Mar 31, 2026 | BOURLA, ALBERT Director, Chairman & CEO | Buy | 21 | $28.08 | $589.68 | - |
| Mar 27, 2026 | SMITH, JAMES C Director | Buy | 1,664 | $27.04 | $45,000.00 | - |
| Mar 27, 2026 | ECHEVARRIA, JOSEPH Director | Buy | 1,710 | $27.04 | $46,250.00 | - |
| Mar 27, 2026 | BUCKLEY, MORTIMER J Director | Buy | 1,387 | $27.04 | $37,499.99 | - |
| Mar 27, 2026 | QUINCEY, JAMES Director | Buy | 1,433 | $27.04 | $38,750.00 | - |
| Mar 27, 2026 | TARAPOREVALA, CYRUS Director | Buy | 1,387 | $27.04 | $37,499.99 | - |
| Mar 27, 2026 | NARAYEN, SHANTANU Director | Buy | 1,849 | $27.04 | $49,999.99 | - |
| Mar 13, 2026 | BOURLA, ALBERT Director, Chairman & CEO | Buy | 1,630 | $26.58 | $43,325.40 | - |
| Mar 4, 2026 | DAMICO, JENNIFER B. SVP & Controller | Sell | 826 | $26.62 | $21,988.12 | - |
| Mar 3, 2026 | BAUM, ANDREW Executive Vice President | Buy | 303,151 | $0.00 | $0.00 | - |
| Mar 3, 2026 | DAMICO, JENNIFER B. SVP & Controller | Buy | 5,408 | $0.00 | $0.00 | - |
| Mar 3, 2026 | DAMICO, JENNIFER B. SVP & Controller | Buy | 22,638 | $0.00 | $0.00 | - |
| Mar 3, 2026 | BOURLA, ALBERT Director, Chairman & CEO | Buy | 708,666 | $0.00 | $0.00 | - |
| Mar 3, 2026 | BOSHOFF, CHRISTOFFEL President, R&D | Buy | 259,844 | $0.00 | $0.00 | - |
| Mar 3, 2026 | DENTON, DAVID M Chief Financial Officer & EVP | Buy | 216,537 | $0.00 | $0.00 | - |
| Mar 3, 2026 | LANKLER, DOUGLAS M Executive Vice President | Buy | 194,883 | $0.00 | $0.00 | - |
| Mar 3, 2026 | MALIK, AAMIR Executive Vice President | Buy | 194,883 | $0.00 | $0.00 | - |
| Mar 3, 2026 | DAMICO, JENNIFER B. SVP & Controller | Buy | 16,311 | $0.00 | $0.00 | - |
| Mar 3, 2026 | FONSECA, LIDIA Executive Vice President | Buy | 82,284 | $0.00 | $0.00 | - |
| Mar 3, 2026 | MCDERMOTT, MICHAEL Executive Vice President | Buy | 151,576 | $0.00 | $0.00 | - |
| Mar 3, 2026 | SAHNI, PAYAL Executive Vice President | Buy | 108,268 | $0.00 | $0.00 | - |
| Mar 3, 2026 | DE, GERMAY ALEXANDRE Executive Vice President | Buy | 194,883 | $0.00 | $0.00 | - |
| Feb 27, 2026 | DAMICO, JENNIFER B. SVP & Controller | Sell | 655 | $27.65 | $18,110.75 | - |
| Feb 26, 2026 | MCDERMOTT, MICHAEL Executive Vice President | Sell | 3,503 | $27.10 | $94,931.30 | - |
| Feb 25, 2026 | FONSECA, LIDIA Executive Vice President | Sell | 1,058 | $27.09 | $28,661.22 | - |
| Feb 25, 2026 | FONSECA, LIDIA Executive Vice President | Buy | 56,888 | $33.82 | $1.92M | - |
| Feb 25, 2026 | BOURLA, ALBERT Director, Chairman & CEO | Sell | 491,626 | $0.00 | $0.00 | - |
| Feb 25, 2026 | BOURLA, ALBERT Director, Chairman & CEO | Sell | 467,241 | $26.92 | $12.58M | - |
| Feb 25, 2026 | BOURLA, ALBERT Director, Chairman & CEO | Sell | 8,303 | $27.09 | $224,928.27 | - |
| Feb 25, 2026 | BOURLA, ALBERT Director, Chairman & CEO | Buy | 491,626 | $33.82 | $16.63M | - |
| Feb 25, 2026 | DAMICO, JENNIFER B. SVP & Controller | Sell | 17,558 | $0.00 | $0.00 | - |
| Feb 25, 2026 | DAMICO, JENNIFER B. SVP & Controller | Sell | 16,687 | $26.92 | $449,214.04 | - |
Insider transactions via Alpha Vantage with SEC EDGAR fallback. Data can include grants, planned sales, and administrative filings; this is not investment advice.
AI Technical Interpretation
PRO turns PFE's RSI, MACD, moving averages, and Bollinger Bands into a plain-English read on trend, momentum, and volatility - context, not predictions.
Upgrade to PROAI Stock Analysis
Unlock an in-depth, balanced bull/bear breakdown of PFE — catalysts, risks, and a plain-language read on the fundamentals.
Upgrade to PRO
About Pfizer Inc.
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Visit pfizer.comKey Statistics
- Open
- $24.15
- Prev Close
- $24.08
- Day High
- $24.24
- Day Low
- $23.74
- Volume
- 49.24M
- Market Cap
- $136.10B
- P/E Ratio
- 18.23
- EPS
- $1.31
- Beta
- 0.29
- Dividend Yield
- +7.20%
- 52W High
- $28.75
- 52W Low
- $23.11
- Analyst Target
- —